Covid-19

#Covid-19 #Immunology / Virology & Vaccines

Oxford AstraZeneca vaccine effective against ‘Kent’ variant

A preprint of ongoing work to assess effectiveness of Oxford’s ChAdOx1 coronavirus vaccine shows that the existing vaccine has similar efficacy against the B.1.1.7 ‘Kent’ coronavirus strain currently circulating in the UK to previously circulating variants. The Oxford University researchers who developed the ChAdOx1-nCoV 19 vaccine have found that it… Read More

#Editor's Choice #News #Trending News

#Clinical trials #Covid-19 #Immunology / Virology & Vaccines

Novavax announces rolling review for COVID-19 vaccine authorisation

Novavax has announced the start of the rolling review process for authorisation of NVX-CoV2373, its COVID-19 vaccine, by multiple regulatory agencies. The reviews will continue while the company completes its Phase III trials in the UK and US and through initial authorisation for emergency use granted under country-specific regulations. “The… Read More

#Covid-19 #Editor's Choice #News

#Covid-19 #Immunology / Virology & Vaccines #Research

Oxford University leads first trial into dosing with alternating vaccines

The University of Oxford has reported  it is to lead the first trial looking into alternating different COVID-19 vaccines, to explore the potential for flexibility in delivery and look for clues as to how to increase the breadth of protection against new virus strains. The study, run by the National… Read More

#Covid-19 #Editor's Choice #News #Trending News

#Covid-19 #Immunology / Virology & Vaccines

GSK and CureVac collaboration to develop COVID-19 vaccine for multi-variants

GlaxoSmithKline and CureVac have signed a €150m (£132m) deal to jointly develop next generation mRNA vaccines for COVID-19. They aim to work together to develop a single vaccine that can address the multiple emerging variants. GSK will also support the manufacture of up to 100 million doses of CureVac’s first… Read More

#Covid-19 #Editor's Choice #News #Trending News

#Covid-19 #Immunology / Virology & Vaccines

Novavax COVID-19 vaccine candidate data at New York Academy of Science

Novavax has announced that Gregory Glenn, President of Research & Development, will present on NVX-CoV2373, the company’s COVID-19 vaccine, at The New York Academy of Science (NYAS) event, ‘The Quest for a COVID-19 Vaccine.’ Webinar details are as follows: Presentation title: Efficacy Data Updates from Novavax’ Protein-based Vaccine Candidate Date:  … Read More

#Covid-19 #News

#Covid-19 #Genomics

US professor calls for better genomic monitoring of COVID-19

The emergence of SARS-CoV-2 virus variants highlight the need for better genomic monitoring of the virus, says Katia Koelle, Associate Professor of Biology at Emory University, Atlanta, Georgia. “Improved genomic surveillance of SARS-CoV-2 across states would really help us to better understand how the virus causing the pandemic is evolving… Read More

#Covid-19 #News #Opinion

#Covid-19 #Immunology / Virology & Vaccines

Janssen COVID-19 vaccine: 66% efficacy in one shot

An investigational COVID-19 vaccine developed by Janssen Pharmaceuticals appears to be safe and effective at preventing moderate and severe COVID-19 in adults, according to an interim analysis of Phase III clinical data. The vaccine, called Ad.26.COV2.S or JNJ-78436725, requires only a single injection and can be stored in a refrigerator… Read More

#Covid-19 #Editor's Choice #News #Trending News

#Covid-19 #Immunology / Virology & Vaccines

Novavax COVID-19 vaccine demonstrates 89.3% efficacy

Novavax, the biotechnology company developing next-generation vaccines for serious infectious diseases, has announced that NVX-CoV2373, its protein-based COVID-19 vaccine candidate, met the primary endpoint, with a vaccine efficacy of 89.3%, in its Phase III clinical trial conducted in the UK. The study assessed efficacy during a period with high transmission… Read More

#Covid-19 #Editor's Choice #News #Trending News

#Covid-19 #CRISPR #Diagnostics

Mammoth Biosciences and Agilent partner on CRISPR-based SARS-CoV-2 diagnostic

Mammoth Biosciences has announced an agreement with Agilent Technologies to support the anticipated launch of a complete CRISPR-based SARS-CoV-2 diagnostic solution comprising Agilent’s Bravo automation workstation and Mammoth Biosciences’ DETECTR BOOSTTM assay. Together, the DETECTR BOOSTTM SARS-CoV-2 kit and Agilent automated liquid handling system would provide a complete workflow for… Read More

#Covid-19 #News